Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug‑resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia

Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Susi Subay, Suko Hari Adiono

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: Bedaquiline is one of the core drugs used to treat multidrug‑resistant TB (MDR‑TB). Delamanid is one of the companion drugs in group C which is used to complete the treatment regimen when drugs in groups A and B can not be used. This study was conducted to analyze the efficacy and safety between individual regimens containing bedaquiline with delamanid and bedaquiline without delamanid. Methods: This was an observational analytic study with a retrospective design in MDR‑TB patients treated with individual regimens containing bedaquiline with delamanid (bedaquiline‑delamanid group) and bedaquiline without delamanid (bedaquiline group). Efficacy was measured according to the time to Acid Fast Bacilli (AFB) conversion and Mycobacterium tuberculosis culture conversion, while safety was measured specifically on QTc interval prolongation. Results: The median (range) time to AFB conversion in bedaquiline‑delamanid group was faster than bedaquiline group, although there was no significant difference (1.5 (1‑4) months vs. 1 (1‑6) months, P=0.429), the median time to culture conversion in bedaquiline‑delamanid group also faster than bedaquiline group, although there was no significant difference (1 (1‑6) months vs. 2 (1‑6) months, P=0.089). The incidence of QTc interval prolongation in bedaquiline‑delamanid group was less than bedaquiline group, although there was no significant difference (26.9% vs. 40.3%, P=0.223). Conclusions: Individual regimens containing bedaquiline with delamanid was proven to provide similar efficacy and safety profiles with individual regimens containing bedaquiline without delamanid. Delamanid should be preferred when selecting drugs to complete the treatment regimen when drugs in groups A and B can not be used.

Original languageEnglish
Pages (from-to)140-146
Number of pages7
JournalInternational Journal of Mycobacteriology
Volume13
Issue number2
DOIs
Publication statusPublished - 2024

Keywords

  • Acid‑fast bacilli conversion
  • Mycobacterium tuberculosis culture conversion
  • QTc interval prolongation
  • bedaquiline
  • delamanid
  • individual regimen
  • multidrug‑resistant tuberculosis

Fingerprint

Dive into the research topics of 'Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug‑resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia'. Together they form a unique fingerprint.

Cite this